ahlam1399
03-22-2016, 04:29 PM
BRIEF-Biopharmx says it received IRB approval to start Phase 4 study of Violet molecular iodine
* Received institutional review board (IRB) approval to initiate phase 4 study of Violet molecular iodine supplement for fibrocystic breast condition & cyclic mastalgia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e6f50f0/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wyszORTch2M:GhKoVIo9po4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wyszORTch2M:GhKoVIo9po4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/wyszORTch2M
* Received institutional review board (IRB) approval to initiate phase 4 study of Violet molecular iodine supplement for fibrocystic breast condition & cyclic mastalgia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e6f50f0/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wyszORTch2M:GhKoVIo9po4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=wyszORTch2M:GhKoVIo9po4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=wyszORTch2M:GhKoVIo9po4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/wyszORTch2M